Doctor shortage across WA causing appointment delays
The shortage could impact already growing wait times and delays in patient appointments.
Here in Washington, we are seeing the impacts.
John Bramhall is an anesthesiologist at Harborview Hospital, the President of the Washington State Medical Association, and a professor at the University of Washington.
'There is a shortage of physicians nationally, in Washington state,' Bramhall told KIRO 7.
He said this has been an ongoing problem for at least five years.
'We hear it all the time, not only from patients but also from clinicians,' Bramhall said.
It's an issue that is expected to get worse. The AAMC projects a need for up to 86,000 doctors by 2036.
He tells us the COVID-19 pandemic, retirements, an aging population, not enough medical school placements, higher demand, and available Medicaid funding are contributing to the delays.
'They find it takes months, not weeks but months, if at all to get connected with an appropriate physician,' Bramhall said.
We spoke with local hospitals to see if they are stretched thin.
Virginia Mason and Providence Swedish Hospital told KIRO 7 they are feeling the impacts and are looking to fill many positions.
Bramhall said Harborview and University of Washington medical groups could use more staff members but aren't under water.
Cassie Sauer, CEO of the Washington State Hospital Association, told us rural clinics are hurting the most, and that is creating bigger issues.
'If someone says I have been having this pain or issue, then if it lingers for six months, it can worsen, and you miss a chance for early intervention. It definitely has impacts on people's health,' Sauer said.
All of the people in this story said that even as medical professionals, they are waiting months for appointments too, telling us this shortage can't and won't be fixed quickly.
Kristy Carrington with Providence Swedish said working on using new technology to help offload paperwork and filter through messages for the doctors will help with burnout rates and appointment delays.
'Recruitment and retention is big here,' she said. She told KIRO 7 that securing funding and positions available and thinking about new ways to provide care will start to shift the shortage issue.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Wire
an hour ago
- Geek Wire
AI model from Microsoft and UW maps out breast cancer in MRIs with unprecedented accuracy
An AI model from researchers at the University of Washington, Microsoft's AI for Good Lab, and Fred Hutchinson Cancer Center creates heatmaps highlighting areas of concern on breast MRI scans. The top row is the original MRI. The second row shows the results from the new tool, compared to other models. (Figure from Oviedo et al in Radiology). New research shows how AI technology can spot breast cancer in MRI scans more accurately than current digital methods, while also pinpointing exactly where suspicious tissue is located — a breakthrough that could make the sensitive screening tool available to more women. The system takes a novel approach by learning what normal breast tissue looks like, then flagging anything unusual, which is the opposite of how cancer-detection AI has typically been built. When it identifies potential cancer, it creates a visual heatmap showing radiologists precisely where to look. Researchers with the University of Washington, Microsoft's AI for Good Lab, and Seattle's Fred Hutchinson Cancer Center were the lead collaborators on the study. Their results were recently published in Radiology, a journal of the Radiological Society of North America. They trained their AI model on roughly 9,500 MRIs collected at the UW between 2005 and 2022. The innovation could help expand access to breast MRI screening, which is more sensitive than mammography but currently limited primarily to high-risk patients due to cost and efficiency concerns. 'We're hoping to be able to offer breast MRI to more women than we do nowadays because it is a really sensitive breast screening tool,' said Savannah Partridge, a UW professor of radiology. 'But to do that, we're looking at how do we scale?' The strategy for building the model flipped the traditional approach on its head. Instead of learning to detect scans that are positive for cancer, the model was trained to recognize normal, or benign, images and then flag MRIs that included abnormal cells. The approach, called 'anomaly detection,' makes sense given that researchers have many more non-cancerous images than those showing disease, said Partridge, 'so we're able to leverage our data more efficiently.' An essential feature of the new tool is that it creates a heatmap overlaying the image, visually highlighting the area of concern. Other technologies sometimes indicate only whether cancer was detected in an MRI, but not precisely where it was found. 'Our model provides an understandable, pixel-level explanation of what's abnormal in a breast,' said Felipe Oviedo, a senior research analyst at Microsoft's AI for Good Lab, in a statement. The AI analysis could help radiologists prioritize cases that need quicker attention, guide providers in additional imaging, or indicate an area that requires a biopsy. The tool is not ready for use in clinical settings. Researchers are planning additional studies to see how the technology performs against radiologists reviewing the same images to better understand its benefits. Partridge, who is the UW's research director of breast imaging and the past associate director of cancer imaging at Fred Hutch, said the collaboration with Microsoft gave her the chance to be closely involved with the creation of the algorithm, providing insight into how it was built and behaved. Still, Partridge wants to proceed with caution when adopting AI for healthcare, ensuring that any clinical tool provides trustworthy, useful information that supports radiologists, rather than complicating their work. 'It's not do you use [AI], or do you not, but how do you use it?' she said. 'How do you use it appropriately and safely?' Additional authors of the study, which was titled 'Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection,' are Anum Kazerouni, Philipp Liznerski, Yixi Xu, Michael Hirano, Robert Vandermeulen, Marius Kloft, Elyse Blum, Adam Alessio, Christopher Li, William Weeks, Rahul Dodhia, Juan Lavista Ferres and Habib Rahbar. Their affiliations include the UW, Microsoft, Fred Hutch, Michigan State University, University of Kaiserslautern-Landau, Berlin Institute for the Foundations of Learning and Data, and Technical University of Berlin.
Miami Herald
2 hours ago
- Miami Herald
Covid-19 drug company liquidates assets in Chapter 11 bankruptcy
When the Covid-19 public health crisis began in the U.S. with the first confirmed case of the 2019 Novel Coronavirus in Washington state on Jan. 20, 2020, the terrifying pandemic was underway, and the Centers for Disease Control and Prevention would report its first confirmed death from the virus on Feb. 29. By March 3, 2020, CDC reported 60 confirmed cases in 12 states. On March 13, the first Trump administration declared a national emergency, and states started implementing shutdowns on March 15, according to the CDC's timeline of Covid-19 events. Don't miss the move: Subscribe to TheStreet's free daily newsletter Biotechnology firms Pfizer-BioTech and Moderna Therapeutics began developing Covid-19 vaccines in March 2020, and by November 2020, each company's Covid-19 vaccine would be found 95% effective in clinical trials. Related: CVS rival pharmacy chain files for Chapter 11 bankruptcy Another biotech firm, Regeneron, in November received approval of an antibody treatment to significantly reduce virus levels within days. In December 2020, Covid-19 vaccinations began, and by Dec. 24, 1 million people had been vaccinated in the U.S. CDC said that by June 1, 2022, the U.S. reported over 84 million Covid-19 infections and over 1 million deaths. About a year later, Pfizer reported on its website that on May 5, 2023, the World Health Organization declared an end to the Covid-19 public health emergency, while the U.S. Department of Health & Human Services did the same on May 11, 2023. The healthcare industry's response to the Covid-19 pandemic was so effective that beginning on May 1, 2024, hospitals were no longer required to report Covid-19 hospital admissions, hospital capacity, or hospital occupancy data to the U.S. Department of Health & Human Services through the Centers for Disease Control and Prevention's National Healthcare Safety Network, according to the CDC website. The end of the crisis also ended the need for massive amounts of Covid-19 drugs. With the Covid-19 pandemic subsiding, companies that stepped forward to develop vaccines, drugs, and treatments during the crisis are now facing declining demand for their services to develop Covid-19 products. With no dire need for Covid-19 products, some drug companies have been forced to downsize or even shut down operations because of a lack of business opportunities. Essential drug manufacturer Aluchua Government Services Inc., which developed Covid-19 therapy drugs under U.S. government contracts, has filed for Chapter 11 bankruptcy with plans to wind down operations and sell its assets. Related: Giant healthcare company files Chapter 11 bankruptcy seeking sale The Aluchua, Fla.-based pharmaceutical company filed its petition in the U.S Bankruptcy Court for the District of Delaware, listing $50 million in assets and $100 million to $500 million in liabilities. The debtor's largest creditors include United States International Development Finance Corp., owed $246 million; Defense Contract Management Agency, owed $11.95 million; and Sigma-Aldrich Inc. $1.33 million. Aluchua was founded in 1999 to develop new drugs and to increase efficacy of existing ones. In 2013, it was awarded a greenfield contract with the U.S. Department of Defense, and in February 2020, it was awarded a contract to develop an advanced monoclonal antibody therapy against Covid-19 infection. The Covid-19 drug was one of several that the debtor partnered with the U.S. government to develop and produce drugs, vaccines, and treatments. The debtor needed to file for Chapter 11 protection after demand for its services began to decline in late 2023 and certain government contracts were wound down or scaled back, according to Aluchua's Chief Restructuring Officer Janet R. Naifeh of FTI Consulting Inc. Aluchua's efforts to replace its government business with commercial contracts failed, which forced it to scale down production and lay off 125 employees from January through April 2025. It reduced its staff by another 67 employees on June 20 and July 1, which, combined with the earlier layoffs, amounted to termination of 80% of its workforce. The company employed 13 full-time and three temporary workers as of the petition date. The company marketed itself for sale beginning in February 2025, but was unable to complete a transaction and decided its only viable option was to file for Chapter 11 bankruptcy, wind down its business, and sell its assets. Related: Iconic retail chain closing its remaining stores in bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
The Hill
2 hours ago
- The Hill
Missouri AG sues Planned Parenthood for allegedly lying about dangers of abortion drugs
Missouri is suing Planned Parenthood for allegedly lying to patients about the risks of the abortion medication mifepristone. Missouri Attorney General Andrew Bailey (R) filed a lawsuit Wednesday in Jefferson City arguing that Planned Parenthood's claims that the abortion drug is safer than many other medications including penicillin and Tylenol are untrue and violate the state's consumer-protection law. Bailey claims that the nonprofit organization has lied about the safety of the drug to 'cut costs and boost revenue,' according to the lawsuit. The complaint also requests a court order to stop Planned Parenthood from 'continuing to promote the falsehoods,' in Missouri and for the organization to pay more than $1.8 million in civil penalties. The attorney general's office is also asking for the organization to be fined $1,000 in damages to every woman in the Show-Me State that has received abortion medication through one of is providers in the past five years. On top of this, it asks that the organization reimburse the state for Medicaid and other tax-payer-funded emergency care provided to people who suffered complications after taking mifepristone. 'We are going to hold these charlatans and death dealers accountable,' Bailey wrote in a post on social platform X about the suit. The crux of the lawsuit's argument comes down to a disagreement over how many people suffer adverse health effects after taking mifepristone. On the Food and Drug Administration's (FDA) warning label for the drug, it states that between 2.9 percent and 4.6 percent of people who have taken it along with misoprostol report visiting an emergency room afterwards. There are two drugs typically needed for a medication abortion: mifepristone and misoprostol. Mifepristone stops the pregnancy from growing while misoprostol induces cramping and bleeding to empty the uterus. More than 100 scientific studies across decades have looked at the efficacy and safety of the pair and all of them have found the drugs safe for use, according to an analysis from The New York Times. Bailey's lawsuit claims that the FDA's label is inaccurate and that 'recent studies' suggest the complication rate is much higher. The lawsuit does not cite a specific study to back up its claim and a spokesperson for the attorney general's office did not answer questions from The Hill about what data was used to back up its claim. The lawsuit does echo findings outlined in a deeply flawed study published in April by the conservative think tank the Ethics and Public Policy Center (EPPC) which states that after analyzing more than 865,000 prescribed mifepristone abortions, it determined that nearly 11 percent of women experienced a 'serious adverse event.' That's nearly 22 times higher than what the FDA reports. Bailey's lawsuit references a 'dataset' of more than 850,000 mifepristone abortions that identified 'serious adverse events' in more than 10 percent of women who took the drug. Medical researchers have criticized the EPPC study for its lack of transparency and for flaws in its methodology. One of the largest hiccups of the study is its inclusion of emergency room visits as one of the 'serious adverse events' that can happen after taking the abortion pill, health experts say. The EPPC study breaks down 'serious adverse events' into categories including hemorrhage, sepsis and emergency room visits. It looks as if emergency room visits were counted as adverse events even if health care workers determined the patient was healthy and released them without treatment. Some people might go to an emergency room after taking the abortion pill to confirm that they are no longer pregnant or to make sure that the bleeding they are experiencing is normal, two principal research scientists at the Guttmacher Institute noted in an op-ed last month. The lawsuit is the latest attack from conservative lawmakers on Planned Parenthood. Under the GOP's new tax and spending bill, the organization would lose its ability to receive Medicaid reimbursements for health services it provides for one year. The nonprofit sued the Trump administration over the provision and a federal judge granted the organization's request for a temporary injunction earlier this week.
